– In SAKURA 3, RT002 was well-tolerated across over 3,800 treatments in glabellar (frown) lines – – The median time to return to baseline glabellar line severity was 28 weeks – – RT002 represents the first long-acting neuromodulator, allowing for two or fewer treatments per year – – Revance announces new trials in forehead lines and lateral canthal lines (crow’s feet) – – Revance to host conference call at 8:30 am ET today –
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.